Article
The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.
Current pharmaceutical design - 1 Jan 2008
Secchiero Paola, di Iasio Maria Grazia, Gonelli Arianna, Zauli Giorgio
Abstract excerpt
At variance to solid tumors, which show percentage of p53 deletions and/or mutations close to 50%, more than 80% of haematological malignancies express wild-type p53 at diagnosis. Therefore, activation of the p53 pathway by antagonizing its negative regulator murine double minute 2 (MDM2) might offer a new therapeutic strategy for the great majority of haematological malignancies. Recently, potent and selective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.